Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

5 June 2017, Bangkok (Thailand) – Doing a rapid test for G6PD deficiency before prescribing the antimalarial drug primaquine to P. vivax malaria patients could be a cost-effective way to improve thousands of lives, say researchers in a study published in PLOS Neglected Tropical Diseases.

Close-up of malaria rapid blood test
Load More

Similar stories

Antimalarial resistance deserves higher priority in global AMR strategy

In a new commentary for BMJ Global Health, University of Oxford researchers argue that antimicrobial resistance (AMR) interventions often ignore morally relevant differences between microbes. They highlight that antimalarial resistance disproportionately affects low- and middle-income countries, particularly children in sub-Saharan Africa, and deserves greater attention in global health research and intervention priorities. The team calls for more equitable resource allocation, policy change, and advocacy to ensure AMR responses are just and inclusive.